Role of the Genomics Revolution in Pharmaceutics

Keywords

Pharmaceutics, Genomics, Computational biology, Medicine, Biology

References

• Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead.Jennifer Arias — 2004
• Individualized drug therapy.Ann K. Daly — 2007
• Prospects and Limits of PharmacogeneticsJan van Aken, Mechtild Schmedders, G??nter Feuerstein — 2003
• Pharmacogenetics as a Molecular Basis for Individualized Drug Therapy: The Thiopurine S-methyltransferase ParadigmEugene Y. Krynetski, William E. Evans — 1999
• Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity.Richard M. Weinshilboum, S. L. Sladek — 1980
• The clinical pharmacology of 6-mercaptopurineLynne Lennard — 2005
• Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.Tong Yin, Toshiyuki Miyata — 2007
• Pharmacogenetics for individualized cancer chemotherapy.Thomas Efferth, M Volm — 2005
• VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulationChristof Geisen, Matthias Watzka, Katja Sittinger — 2005
• Pharmacogenomics and drug response in cardiovascular disorders.Gérard Siest, Élise Jeannesson, Hind Berrahmoune — 2004
• Pharmacogenetics and the concept of individualized medicineB.S. Shastry — 2006
• Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity.Hung-Liang Tai, Eugene Y. Krynetski, Erin G. Schuetz — 1997
• Human pharmacogenomics: The development of a scienceW. Kalow — 2004
• Integrating genotype and phenotype information: an overview of the PharmGKB projectTeri E. Klein, Jean Chang, Mildred K. Cho — 2001
• Thiopurine pharmacogenetics in leukemia: Correlation of erythrocyte thiopurine methyltransferase activity and 6‐thioguanine nucleotide concentrationsLynne Lennard, Jon A. Van Loon, John Lilleyman — 1987
• Pharmacogenetics and Pharmacogenomics in Drug Discovery and Development: An OverviewKlaus Lindpaintner — 2003
• Thiopurine S-methyltransferase pharmacogenetics: chaperone protein association and allozyme degradation.Liewei Wang, W. Patrick Sullivan, David O. Toft — 2003
• Pharmacogenomics: bench to bedsideRichard M. Weinshilboum, Liewei Wang — 2004
• Can personalized drug therapy be achieved? A closer look at pharmaco-metabonomics.Daniel W. Nebert, Elliot S. Vesell — 2006
• Pharmacogenomics and individualized drug therapy.Michel Eichelbaum, Magnus Ingelman‐Sundberg, William E. Evans — 2006

Cited by

No citing papers recorded for this paper.

Related papers

• Structural genomics: opportunities and challenges.Peer R. E. Mittl, Markus G. Grütter — 2001
• Chemical genomics: a systematic approach in biological research and drug discovery.X.F. Steven Zheng, Ting‐Fung Chan — 2002
• Functional genomics and proteomics: charting a multidimensional map of the yeast cell.Gary D. Bader, Adrian Heilbut, Brenda Andrews — 2003
• Spatially resolved transcriptomics adds a new dimension to genomicsLudvig Larsson, Jonas Frisén, Joakim Lundeberg — 2021
• The Dictionary of Gene Technology: Genomics, Transcriptomics, ProteomicsGuruprasad Madhavan — 2005
• Comparative population genomics: power and principles for the inference of functionalityDavid S. Lawrie, Dmitri A. Petrov — 2014
• Microbial genomics – new targets, new drugsMolly B. Schmid — 2001
• Novel approaches in function-driven single-cell genomicsDevin F. R. Doud, Tanja Woyke — 2017
• The promise of structural genomics in the discovery of new antimicrobial agents.Sean G. Buchanan, J.M. Sauder, Tess Harris — 2002